Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...

When a parent’s health declines, doctors must navigate difficult, overlapping roles, balancing clinical knowledge with ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Edward S. Cooper, MD, the American Heart Association’s first Black president, leaves behind an indelible mark on stroke ...

In a 10-year study of postmenopausal women, tea consumption shows a small but significant benefit for bone mineral density, ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how emerging research in paroxysmal nocturnal ...

Growth hormone replacement therapy improves physical fitness, lifestyle habits, and quality of life in children with growth ...

Christmas traditions such as decorating a tree and singing not only lift spirits but also boost immunity by triggering immune ...

Menopause hormone therapy neither increases nor decreases the risk for dementia or mild cognitive impairment in ...

A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...